HMGB1 and acute lymphoblastic leukemia: Compared with the healthy control and ALL patients with complete remission, serum HMGB1 level of ALL patients was increased, but there was no significant difference in HMGB1 level between the healthy control group and ALL complete remission group, indicating that serum HMGB1 is a useful biomarker to evaluate the prognosis of childhood ALL.